Research programme: A2AR allosteric modulators - Adoram Therapeutics
Latest Information Update: 12 Dec 2022
At a glance
- Originator Adoram Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Adenosine A2A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 30 Nov 2022 Adoram Therapeutics has patent pending application for NMA (Adoram Therapeutics website, November 2022)
- 30 Nov 2022 Early research in Cancer in Switzerland (parenteral) before November 2022 (Adoram Therapeutics website, November 2022)
- 30 Nov 2022 Preclinical trials in Cancer in Switzerland (Parenteral) before November 2022 (Adoram Therapeutics website, November 2022)